Evaluation of the Effectiveness of Music Therapy on Anxiety Levels in Patients With Advanced Cancer Hospitalized in a Palliative Care Unit

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire, Amiens

About this trial

A music therapy intervention can be either receptive or active. In both cases, somatic effects have been observed, with a direct impact on respiratory, cardiac and hemodynamic parameters, as well as psychological effects, creating a relationship of support, accompaniment and listening to the person. An intervention protocol using Kigonki has been developed and validated by the University Diploma in Music Therapy team at Paul-Valéry Montpellier 3 University (DUMM3). Studies on music therapy in palliative care have been published, but there is still a need for large controlled studies assessing the prolonged effect of a standardized intervention. This randomized clinical is designed for patients with terminal cancer pathology, hospitalized in palliative care units and with anxiety and depression scores both above 11 on the Hospital Anxiety and Depression scale (HAD). The primary endpoint is change in anxiety score. Patients included in the experimental arm will be offered the above-mentioned protocol with 3 weekly sessions of receptive music therapy with Kigonki for 2 weeks, after drawing up an intervention plan. Anxiety/depression levels will be measured before and 30 minutes after each session, as well as one week after the last session. Patients in the reference arm will have their anxiety/depression level monitored 3 times a week. In both arms, the study will be terminated at the end of the last protocol evaluation (i.e., at 3 weeks). If anxiety worsens (score rises by 2 points), a music therapy intervention similar to that performed for patients of the experimental arm may be proposed to patients of the reference arm. This project requires the participation of 84 patients, which seems feasible at the inter-regional level in 7 centers over 18 months.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age > 18 years

Patient hospitalized in palliative care unit for oncological pathology

Presenting an anxiety score > 46 (according to the STAI-Y State scale)

Whose subsequent hospitalization is estimated to last more than three weeks

Disqualifiers

Deafness without hearing aids

Patients under guardianship, curatorship or safeguard of justice

Pregnant or breast-feeding

Not affiliated to a social security scheme

Trial design

Design model

Parallel

Treatments tested in this trial

  • depression management

    Other intervention

    \- Management of anxiety, pain, and depression according to the usual pharmacological and non-pharmacological practices of each center.

  • Kigonki

    Other intervention

    Six 30-minute sessions of receptive ISM with Kigonki according to study protocol

  • questionnaire

    Other intervention

    Assessment of PANAS questionnaire, TSAI test, digital scale measurement, physiological constants (pulse, blood pressure, respiratory rate) 3 times a week for 2 weeks, then 7 days after the last of these 6 assessments.

Treatment groups

84 Participants
are divided into 2 treatment groups
Group A: Group without music therapyActive comparator 2 interventions
Group B: Music therapy groupExperimental treatment 3 interventions

Trial outcomes

Primary outcomes

1

change in anxiety score obtained using the STAI-Y State scale

The State-Trait Anxiety Inventory (STAI), specifically Form Y (STAI-Y), stands as one of the most widely utilized self-report measures in psychological and medical research for the quantitative assessment of anxiety. The STAI-Y operationalizes the psychological construct of anxiety as having two independent dimensions, each measured by 20 items for a total of 40 items in the complete inventory. State Anxiety (A-State) is defined as a transient emotional response characterized by immediate, subjective feelings of tension, apprehension, worry, and physiological activation of the autonomic nervous system. Respondents assess their feelings "right now, at this moment" using a 4-point intensity scale. In contrast, Trait Anxiety (A-Trait) refers to stable individual differences in anxiety proneness. Individuals scoring high in A-Trait are predisposed to perceive a broader range of situations as threatening and are likely to react to these situations with elevated A-State responses. A-Trait

Time frame
1 week
2

change in anxiety score obtained using the STAI-Y State scale

The State-Trait Anxiety Inventory (STAI), specifically Form Y (STAI-Y), stands as one of the most widely utilized self-report measures in psychological and medical research for the quantitative assessment of anxiety. The STAI-Y operationalizes the psychological construct of anxiety as having two independent dimensions, each measured by 20 items for a total of 40 items in the complete inventory. State Anxiety (A-State) is defined as a transient emotional response characterized by immediate, subjective feelings of tension, apprehension, worry, and physiological activation of the autonomic nervous system. Respondents assess their feelings "right now, at this moment" using a 4-point intensity scale. In contrast, Trait Anxiety (A-Trait) refers to stable individual differences in anxiety proneness. Individuals scoring high in A-Trait are predisposed to perceive a broader range of situations as threatening and are likely to react to these situations with elevated A-State responses. A-Trait

Time frame
2 weeks

Secondary outcomes

1

PANAS questionnaire (Positive and Negative Affect Scale)

Time frame
30 minutes after the session
2

Variations in scores of the STAI-Y ETAT scale

Time frame
30 minutes after the session
3

pulse variation

Time frame
30 minutes after the session
4

BP variation

Time frame
30 minutes after the session

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Centre Hospitalier Universitaire, Amiens

Lead sponsor

Centre Hospitalier de Bethune

Collaborator

Centre Hospitalier de Douai

Collaborator

Hospital of Lens

Collaborator

GHPSO site de Senlis

Collaborator

CH de Compiegne

Collaborator

Centre Hospitalier de Beauvais

Collaborator

This trial is not recruiting at the moment. You can still explore other options: